See also this year's filing and all EDGAR filings for this company.
PDF Report 0001355250_2021_Innovation_Pharmaceuticals_Inc.pdf
Logs
| warning | No LiabilitiesAndStockholdersEquity node found | input.sec.calculation_linkbase.edgar_model_mapping | {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'OtherAssets', 'CashAndCashEquivalentsAtCarryingValue', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'AccruedEnvironmentalLossContingenciesNoncurrent', 'OperatingLeaseLiabilityNoncurrent', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'AccruedSalariesCurrent', 'OperatingLeaseLiabilityCurrent', 'NotesPayableRelatedPartiesClassifiedCurrent', 'LoansPayableCurrent', 'AccruedDividendSeriesB5ConvertiblesPreferredStock', 'FiniteLivedPatentsGross', 'PropertyPlantAndEquipmentNet', 'SecurityDeposit'))"} |
Graph
Absolute values for 0001355250, Innovation Pharmaceuticals Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 6,110,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 0 |
| 3 | remainder_Assets | 3,138,000 |
| 4 | LiabilitiesCurrent | 7,369,000 |
| 5 | LiabilitiesNoncurrent | 417,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 1,429,000 |
| 9 | ResearchAndDevelopmentExpense | 2,792,000 |
| 10 | remainder_Expenses | 4,549,000 |
| 11 | remainder_Revenues | 423,000 |
| 12 | remainder_NetIncome | -6,546,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 9,248,000 |
| 1 | Liabilities | 7,786,000 |
| 2 | Expenses | 8,770,000 |
| 3 | Revenues | 423,000 |
| 4 | StockholdersEquity | 1,462,000 |
| 5 | NetIncome | -14,893,000 |
| 6 | ComprehensiveNetIncome | -14,893,000 |
| 7 | BaseVar | 16,386,500 |
| 8 | EconomicCapitalRatio | -1.45 |
Edgar->Model Mapping
Feature Distribution
Change over Time
